Dr. Ross Camidge, University of Colorado, discusses management of CNS progression for ALK-positive NSCLC including monitoring frequency and preferences between systemic and radiation therapy.

Here is a brief and basic summary of the concept of why we're concerned not only about the cancer we can see but the potential cancer we can't.

Here's a brief video just discussing the rationale for why a systemic treatment like chemotherapy is recommended not only as the cornerstone of treatment for advanced lung cancers, which makes intuitive sense, but also for the majority of patients with earlier stages of lung cancer as well.

[powerpress]

I hope it's helpful.

We've covered the potential value of systemic therapy for early stage NSCLC in a wide range of posts and podcasts, and to summarize what we've learned in a sentence, it's basically that chemotherapy can significantly increase progression-free survival (PFS) and overall survival (OS) in patients who have undergone curative surgery for stage I-III NSCLC, but the benefit is far more convincing in patients with a high enough risk to justify the potential adverse effects of chemotherapy.